Trump’s executive order to cap U.S. costs risks limiting the supply of new pharmaceuticals. President Donald Trump’s ...

Billionaire pharmaceuticals company owner Dennis Bastas is firming as the likely buyer behind Melbourne's priciest ever home ...

Ken Hall takes a closer look at GSK after the FTSE 100 pharmaceutical giant's positive first quarter earnings update.

Government signs deal to see huge investment in mRNA vaccine manufacturing which could help tackle the next pandemic and ...

It’s also worth noting that ... its impact on Indian pharmaceutical companies is likely to be uneven. Generic-focused players will not be affected much and may even benefit from a more level ...

Trump has just signed an order that could hike drug prices around the world and he will soon announce pharmaceutical tariffs.

The ink on Britain’s landmark post-Brexit trade deal with India had hardly dried before the news broke that an agreement with ...

AI-driven drug discovery has gotten much of the glory ... throughout pharma. While shaving time off of drug discovery for a single asset can be a boon for one company, Owens sees wider value ...

WD-40 Deutsche Bank’s Binky Chadha analyzed the data to estimate how much extra ... for S&P 500 companies is arguably significant, it doesn’t even buy a quarter’s worth of time.

Today we hear from Jeremy Spivey about clinical trial outsourcing, and whether pharma companies should be looking ... of the trial process is in no way worth delays in product approval that ...

UnitedHealth Group faces real PBM reform risks, but legal paths, financials, and market pricing suggest opportunity in ...

we could make the case it ought to be worth 45% as much, i.e., have a market cap just above $5bn. On the other hand, Dr. Reddy's is a profitable company, generating >$670m of net income last year ...